Novavax, Inc. (NASDAQ:NVAX) Stock Has Average Price Target of $12.33 According to Analysts

Shares of Novavax, Inc. (NASDAQ:NVAX) have received a consensus rating of “Hold” from the ten brokerages that are presently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $12.33.

NVAX has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Novavax in a research report on Tuesday, August 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Novavax in a report on Tuesday, October 27th. Citigroup reaffirmed a “sell” rating and set a $8.00 price target (up from $7.00) on shares of Novavax in a report on Thursday, October 15th. Wall Street Zen upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Finally, Zacks Research cut shares of Novavax from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th.

Institutional Investors Weigh In On Novavax

Several institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new position in shares of Novavax during the 2nd quarter valued at about $8,004,000. Squarepoint Ops LLC purchased a new position in shares of Novavax during the 2nd quarter worth $1,258,000. Renaissance Technologies LLC acquired a new stake in shares of Novavax in the first quarter valued at about $4,049,000. Edgestream Partners L.P. acquired a new stake in shares of Novavax during the first quarter worth $4,234,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Novavax during the 2nd quarter worth about $739,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Stock Performance

Shares of Novavax stock opened at $10.08 on Friday. The firm has a market cap of $1.66 billion, a PE ratio of -6.63 and a beta of 2.65. The stock has a 50 day moving average of $10.46 and a 200 day moving average of $9.30. Novavax has a 12 month low of $6.20 and a 12 month high of $13.39.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.06. The firm had revenue of $56.70 million for the quarter, compared to analyst estimates of $52.51 million. Novavax had a negative return on equity of 14.82% and a negative net margin of 59.87%. Novavax’s revenue for the quarter was down 76.2% compared to the same quarter last year. During the same period last year, the company earned $0.62 earnings per share. As a group, equities research analysts forecast that Novavax will post -0.38 earnings per share for the current fiscal year.

Novavax News Summary

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Sanofi triggered a $125 million milestone payment. Sanofi’s initiation of a European Phase 3 trial for an influenza-COVID-19 combination vaccine—after the fifth patient was dosed—earned Novavax the payment under their collaboration and license agreement. The trial uses Novavax’s Nuvaxovid COVID-19 vaccine with Sanofi’s high-dose flu vaccine. The cash payment is meaningful relative to Novavax’s roughly $1.66 billion market value and supports near-term liquidity. Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
• Positive Sentiment: The Sanofi collaboration retains additional upside through potential future milestones and royalties. A successful combination vaccine could give Novavax exposure to global flu and COVID-19 markets valued at more than $10 billion combined, although commercialization remains dependent on trial results and regulatory approvals. Novavax Earns $125 Million Milestone Payment From Sanofi’s Phase 3 Vaccine Trial in Europe
• Neutral Sentiment: Brokerages have a consensus price target of $12.33, above the recent trading level, but the target reflects mixed analyst views and is not a guarantee of further gains. Novavax Stock Has Consensus Target Price of $12.33 According to Brokerages
• Neutral Sentiment: Novavax will report third-quarter 2026 results before the market opens on November 5, followed by a management webcast. The event could provide updates on vaccine demand, cash flow and the Sanofi partnership. Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
• Negative Sentiment: Analysts and Zacks warn that Novavax may report another negative quarter and lacks the favorable earnings and estimate-revision trends typically associated with a likely earnings beat. That concern may be limiting the stock’s response to the Sanofi payment. Novavax May Report Negative Earnings

About Novavax

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.